Trial reportBMC medicine2026
Impact of reduced-frequency monitoring among users of HIV pre-exposure prophylaxis on sexually transmitted infections and associated care: secondary outcomes of a randomized controlled trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05093036 (The EZI-PrEP Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The EZI-PrEP Study: E-Health for Zero Infections - Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in the Netherlands
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOral HIV pre-exposure prophylaxis (PrEP) users are generally screened for sexually transmitted infections (STIs) every 3 months. The need for such frequent screening is debatable. We compared STI diagnoses and associated care between PrEP users who underwent 6-monthly versus 3-monthly PrEP monitoring.
methodsWe conducted a secondary analysis of the EZI-PrEP study- a 2 × 2 factorial randomized controlled trial examining 6-monthly versus 3-monthly and online versus in-clinic PrEP monitoring among men who have sex with men (MSM) and transgender or gender-diverse persons in the Netherlands (2021-2024). Participants were followed for 24 months. Scheduled PrEP monitoring included bacterial STI screening (i.e., Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), syphilis). Unscheduled STI testing in-between monitoring visits was permitted. This secondary analysis compared several outcomes between the 6-monthly and 3-monthly monitoring groups, using Poisson regression: (i) visit rates as number of visits per person-year (PY), (ii) STI detection rates as number of STI diagnoses per 100PY (to assess STI detection and potential (over)treatment), and (iii) STI positivity as number of STI diagnoses per 100 visits (as proxy for diagnostic delay). We stratified outcomes by visit type (i.e., scheduled/unscheduled) and adjusted for sexual behavior.
results451 participants (99% MSM) were followed for median 22.7 months (IQR 19.2-23.8). Compared to 3-monthly PrEP monitoring, 6-monthly monitoring led to 31% fewer visits in total (rate ratio = 0.69, 95%CI = 0.64-0.74), but 67% more unscheduled visits (rate ratio = 1.67, 95%CI = 1.42-1.98). The STI detection rate was 18% lower in the 6-monthly monitoring group (adjusted rate ratio = 0.82, 95%CI = 0.70-0.95). STI positivity at PrEP monitoring visits did not differ between monitoring groups (6-monthly: 23.8 STIs/100 visits; 3-monthly: 23.2 STIs/100 visits; adjusted positivity ratio = 1.09, 95%CI = 0.90-1.30).
conclusionsReduced-frequency PrEP monitoring resulted in fewer total clinic visits, but more self-initiated STI testing. Furthermore, fewer STIs were diagnosed during follow-up, yet the number of STIs detected per scheduled monitoring visit was similar between groups. These findings suggest that less frequent PrEP monitoring could reduce the burden of PrEP care and the number of STIs that are detected and treated, without leading to a substantial rise in STIs.
trial registrationThe trial has been registered with ClinicalTrials.gov, trial number NCT05093036 ( https://clinicaltrials.gov/study/NCT05093036 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.